医学
巴斯代人
强直性脊柱炎
轴性脊柱炎
抗风湿药物
物理疗法
内科学
逻辑回归
痹症科
疾病严重程度
脊柱炎
子群分析
抗风湿药
疾病
成果研究
巴斯菲
作者
Stylianos Georgiadis,Lykke Midtbøll Ørnbjerg,Brigitte Michelsen,Tore K Kvien,Mehrdad Shoae Kazemi,Kristýna Bubová,Herman F. Mann,Karel Pavelká,Bente Glintborg,Anne Gitte Loft,Helena Santos,Andreas Reich,Anne C. Regierer,Jarno Rutanen,Laura Kuusalo,Gary John Macfarlane,Gareth Tudor Jones,Adrian Ciurea,Michael John Nissen,Björn Guðbjörnsson
标识
DOI:10.3899/jrheum.2026-0445
摘要
OBJECTIVE: To compare a newly proposed Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cut-off for high disease activity (BASDAI≥2.5) with the corresponding Axial Spondyloarthritis Disease Activity Score (ASDAS) cut-off (ASDAS≥2.1) as an eligibility criterion for initiating a biologic disease-modifying antirheumatic drug (bDMARD) in routine care patients with axial spondyloarthritis (axSpA). METHODS: Real-world patients with axSpA initiating their first bDMARD from 9 European registries were analysed. Patients were categorised into 4 subgroups according to the fulfilment of ASDAS and BASDAI criteria at baseline, and treatment effect was assessed at 6 months using several response and remission outcomes. Adjusted logistic regression analyses were performed to determine whether fulfilling ASDAS and BASDAI criteria was associated with achieving the treatment outcomes. RESULTS: Of 6,329 patients included, 90.9% fulfilled both ASDAS and BASDAI eligibility criteria at baseline, 2.5% and 2.7% fulfilled either ASDAS or BASDAI criterion alone, while 3.8% fulfilled neither. The subgroup fulfilling both criteria demonstrated the highest responses at 6 months, while the highest remission outcomes were observed in the subgroup fulfilling neither criterion. Fulfilling either criterion at baseline was significantly associated with achieving response outcomes at 6 months, whereas a negative association was observed for remission outcomes. CONCLUSION: In a multinational European cohort, a very large overlap between the BASDAI and the ASDAS eligibility criteria was shown, and the predictive ability of the two criteria to achieve treatment outcomes was comparable. These findings support the use of BASDAI≥2.5 as a criterion for initiating bDMARD therapy in axSpA, particularly when ASDAS is unavailable.
科研通智能强力驱动
Strongly Powered by AbleSci AI